$85 0.0 0.0%
Last Trade - 5:22pm
| Market Cap | £54.9m |
| Enterprise Value | £49.5m |
| Revenue | £38.7m |
| Position in Universe | 5216th / 6651 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st May | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 28.9 | 33.1 | 36.6 | 35.9 | 39.5 | 46.4 | +9.9% | ||||
| +566.6 | +49.9 | +38.7 | -9.8 | -23.0 | +53.7 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Bioqual, Inc. is a provider of research, development, consulting and testing/assay services to commercial clients and Government laboratories. The Company supports the National Institutes of Health by providing research services in the research areas of cancer, acquired immune deficiency syndrome (AIDS), hepatitis, influenza, immunology, transgenics, contraception, breeding and development of genetically defined animals, and neurobiology and behavior. The Company's research contracts consist of cancer virus studies, congenic animal development and monoclonal antibody research. The Company's research services include primate biology and medicine, small laboratory animal sciences, infectious disease research, in vitro laboratory services, environmental enrichment and behavior, good laboratory practice (GLP) studies, and partnerships for contracts and grants. The Company holds government contracts, which utilize the non-human primate model to study assorted human diseases.
| Last Annual | May 31st, 2020 |
| Last Interim | November 30th, 2020 |
| Incorporated | January 5, 1982 |
| Public Since | July 14, 1983 |
| No. of Shareholders: | n/a |
| No. of Employees: | 108 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | Pink Sheets on Nasdaq |
| Shares in Issue | 894,416 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 4 Research Ct, ROCKVILLE, 20850-3220, United States |
| Web | http://www.bioqual.com/ |
| Phone | +1 240 4047654 |
| Contact | () |
| Auditors | Aronson & Co |
As of 5:22pm, shares in Bioqual Inc are trading at $85, giving the company a market capitalisation of £54.9m. This share price information is delayed by 15 minutes.
Shares in Bioqual Inc are currently trading at $85 and the price has moved by 54.55% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioqual Inc price has moved by 20.61% over the past year.
There are no analysts currently covering Bioqual Inc.
Bioqual Inc is scheduled to issue upcoming financial results on the following dates:
The Bioqual Inc dividend yield is 0.82% based on the trailing twelve month period.
Last year, Bioqual Inc paid a total dividend of 0.7, and it currently has a trailing dividend yield of 0.82%. Looking ahead, Bioqual Inc has not announced an ex-dividend date yet.
Bioqual Inc has yet to annouce their ex-dividend date. The historic dividend yield on Bioqual Inc shares is currently 0.82%.
To buy shares in Bioqual Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Bioqual Inc are currently trading at $85, giving the company a market capitalisation of £54.9m.
Here are the trading details for Bioqual Inc:
Based on an overall assessment of its quality, value and momentum, Bioqual Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Bioqual Inc.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioqual Inc. Over the past six months, the relative strength of its shares against the market has been 12.96%. At the current price of $85, shares in Bioqual Inc are trading at 57.21% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioqual Inc PE ratio based on its reported earnings over the past 12 months is 14.5. The shares are currently trading at $85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioqual Inc's management team is headed by:
Here are the top five shareholders of Bioqual Inc based on the size of their shareholding:
